{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:52:43Z","timestamp":1791186763557,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,8,21]],"date-time":"2015-08-21T00:00:00Z","timestamp":1440115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,8,21]],"date-time":"2015-08-21T00:00:00Z","timestamp":1440115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Cholestasis induces adaptive mechanisms protecting the liver against bile acids (BA) toxicity including modulation of BA synthesis. Whether fibroblast growth factor 19 (FGF19) or farnesoid X receptor (FXR) dependent signaling are involved in the regulation of BA homeostasis in primary biliary cirrhosis (PBC) remains unknown. Here we analyzed hepatic expression of FGF19 and other genes relevant to the adaptive response to cholestasis in tissues from non-cirrhotic (n\u2009=\u200924) and cirrhotic (n\u2009=\u200921) patients along with control tissues (n\u2009=\u200921). Moreover we searched for relationships between serum FGF19 and laboratory\/clinical findings in 51 patients. Hepatic FGF19 mRNA expression was increased in non-cirrhotic and cirrhotic tissues (9-fold,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.01; 69-fold,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0001, respectively). Protein levels of FGF19, FGF receptor 4, FXR and short heterodimer partner were increased in cirrhotic livers (9-fold,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001; 3.5-fold,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.007; 2.4-fold,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0001; 2.8-fold,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0001\n                    <jats:italic>vs<\/jats:italic>\n                    controls, respectively) which was accompanied by down-regulation of CYP7A1 (50% reduction,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.006). Serum and liver levels of FGF19 correlated with worse liver biochemistry, BAs, quality of life and Mayo Risk Score. Serum FGF19 was elevated in UDCA non-responders. We conclude that PBC induces characteristic changes in liver expression of BAs synthesis regulatory molecules. FGF19 correlates with severity of liver disease and can potentially serve as an indicator of chronic cholestatic liver injury.\n                  <\/jats:p>","DOI":"10.1038\/srep13462","type":"journal-article","created":{"date-parts":[[2015,8,21]],"date-time":"2015-08-21T06:07:10Z","timestamp":1440137230000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["Expression of hepatic Fibroblast Growth Factor 19 is enhanced in Primary Biliary Cirrhosis and correlates with severity of the disease"],"prefix":"10.1038","volume":"5","author":[{"given":"Ewa","family":"Wunsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Milkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urszula","family":"Wasik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn","family":"Trottier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Kempi\u0144ska-Podhorodecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elwyn","family":"Elias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Barbier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Milkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,8,21]]},"reference":[{"key":"BFsrep13462_CR1","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1056\/NEJMra043898","volume":"22","author":"MM Kaplan","year":"2005","unstructured":"Kaplan, M. M. & Gershwin, M. E. Primary biliary cirrhosis. N Engl J Med. 22, 1261\u20131273. (2005)","journal-title":"N Engl J Med."},{"key":"BFsrep13462_CR2","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1136\/gut.2003.025155","volume":"53","author":"P Milkiewicz","year":"2004","unstructured":"Milkiewicz, P. & Heathcote, E. J. Fatigue in chronic cholestasis. Gut. 53, 475\u2013477 (2004)","journal-title":"Gut."},{"key":"BFsrep13462_CR3","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/hep.22371","volume":"48","author":"JL Newton","year":"2008","unstructured":"Newton, J. L. et al. Cognitive impairment in primary biliary cirrhosis: symptom impact and potential etiology. Hepatology. 48, 541\u2013549 (2008)","journal-title":"Hepatology"},{"key":"BFsrep13462_CR4","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.4049\/jimmunol.138.10.3525","volume":"15","author":"ME Gershwin","year":"1987","unstructured":"Gershwin, M. E., Mackay, I. R., Sturgess, A. & Coppel, R. L. Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. J Immunol. 15, 3525\u20133531 (1987)","journal-title":"J Immunol."},{"key":"BFsrep13462_CR5","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.jhep.2005.03.017","volume":"43","author":"C Pauli-Magnus","year":"2005","unstructured":"Pauli-Magnus, C., Stieger, B., Meier, Y., Kullak-Ublick, G. A. & Meier, P. J. Enterohepatic transport of bile salts and genetics of cholestasis. J Hepatol. 43, 342\u2013357 (2005)","journal-title":"J Hepatol."},{"key":"BFsrep13462_CR6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/01.mcg.0000155551.37266.26","volume":"39","author":"M Trauner","year":"2005","unstructured":"Trauner, M., Wagner, M., Fickert, P. & Zollner, G. Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis. J Clin Gastroenterol. 39(4 Suppl 2), 111\u2013124 (2005)","journal-title":"J Clin Gastroenterol."},{"key":"BFsrep13462_CR7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cmet.2005.09.001","volume":"2","author":"T Inagaki","year":"2005","unstructured":"Inagaki, T. et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2, 217\u2013225 (2005)","journal-title":"Cell Metab."},{"key":"BFsrep13462_CR8","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1101\/gad.1083503","volume":"1","author":"JA Holt","year":"2003","unstructured":"Holt, J. A. et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 1, 1581\u20131591 (2003)","journal-title":"Genes Dev."},{"key":"BFsrep13462_CR9","doi-asserted-by":"publisher","first-page":"G923","DOI":"10.1152\/ajpgi.00490.2005","volume":"290","author":"G Zollner","year":"2006","unstructured":"Zollner, G. et al. Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-alpha\/beta in the adaptive response to bile acids. Am J Physiol Gastrointest Liver Physiol. 290, G923\u2013G932. (2006)","journal-title":"Am J Physiol Gastrointest Liver Physiol."},{"key":"BFsrep13462_CR10","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/nm1501","volume":"12","author":"M Choi","year":"2006","unstructured":"Choi, M. et al. Identification of a hormonal basis for gallbladder filling. Nat Med. 12, 1253\u20131255 (2006)","journal-title":"Nat Med"},{"key":"BFsrep13462_CR11","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1210\/en.2003-1671","volume":"145","author":"L Fu","year":"2004","unstructured":"Fu, L. et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology. 145, 2594\u20132603 (2004)","journal-title":"Endocrinology."},{"key":"BFsrep13462_CR12","doi-asserted-by":"publisher","first-page":"e17868","DOI":"10.1371\/journal.pone.0017868","volume":"6","author":"AL Wu","year":"2011","unstructured":"Wu, A. L. et al. FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways. PLoS One. 6, e17868 (2011)","journal-title":"PLoS One."},{"key":"BFsrep13462_CR13","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nrd2792","volume":"8","author":"A Beenken","year":"2009","unstructured":"Beenken, A. & Mohammadi, M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 8, 235\u2013253 (2009)","journal-title":"Nat Rev Drug Discov"},{"key":"BFsrep13462_CR14","doi-asserted-by":"publisher","first-page":"G940","DOI":"10.1152\/ajpgi.00398.2012","volume":"304","author":"JH Zhang","year":"2013","unstructured":"Zhang, J. H. et al. Potent stimulation of fibroblast growth factor 19 expression in the human ileum by bile acids. Am J Physiol Gastrointest Liver Physiol. 304, G940\u2013G948 (2013)","journal-title":"Am J Physiol Gastrointest Liver Physiol."},{"key":"BFsrep13462_CR15","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jsbmb.2011.06.012","volume":"130","author":"JW Jonker","year":"2012","unstructured":"Jonker, J. W., Liddle, C. & Downes, M. FXR and PXR: potential therapeutic targets in cholestasis. J Steroid Biochem Mol Biol. 130, 147\u2013158 (2012)","journal-title":"J Steroid Biochem Mol Biol."},{"key":"BFsrep13462_CR16","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1002\/hep.21183","volume":"43","author":"T Li","year":"2006","unstructured":"Li, T., Jahan, A. & Chiang, J. Y. Bile acids and cytokines inhibit the human cholesterol 7 alpha-hydroxylase gene via the JNK\/c-jun pathway in human liver cells. Hepatology 43, 1202\u20131210 (2006)","journal-title":"Hepatology"},{"key":"BFsrep13462_CR17","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1101\/gad.1773909","volume":"15","author":"J Miao","year":"2009","unstructured":"Miao, J. et al. Bile acid signaling pathways increase stability of Small Heterodimer Partner (SHP) by inhibiting ubiquitin-proteasomal degradation. Genes Dev. 15, 986\u2013996 (2009)","journal-title":"Genes Dev."},{"key":"BFsrep13462_CR18","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/hep.25740","volume":"56","author":"B Kong","year":"2012","unstructured":"Kong, B. et al. Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice. Hepatology. 56, 1034\u20131043 (2012)","journal-title":"Hepatology"},{"key":"BFsrep13462_CR19","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1002\/hep.22771","volume":"49","author":"FG Schaap","year":"2009","unstructured":"Schaap, F. G., van der Gaag, N. A., Gouma, D. J. & Jansen, P. L. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology 49, 1228\u20131235 (2009)","journal-title":"Hepatology"},{"key":"BFsrep13462_CR20","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/hep.22627","volume":"49","author":"KH Song","year":"2009","unstructured":"Song, K. H., Li, T., Owsley, E., Strom, S. & Chiang, J. Y. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression. Hepatology 49, 297\u2013305 (2009)","journal-title":"Hepatology"},{"key":"BFsrep13462_CR21","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S0167-4781(98)00255-3","volume":"18","author":"T Nishimura","year":"1999","unstructured":"Nishimura, T., Utsunomiya, Y., Hoshikawa, M., Ohuchi, H. & Itoh, N. Structure and expression of a novel human FGF, FGF-19, expressed in the fetal brain. Biochim Biophys Acta. 18, 148\u2013151 (1999)","journal-title":"Biochim Biophys Acta."},{"key":"BFsrep13462_CR22","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1053\/j.gastro.2011.10.028","volume":"142","author":"S Modica","year":"2012","unstructured":"Modica, S. et al. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. Gastroenterology. 142, 355\u2013365 (2012)","journal-title":"Gastroenterology."},{"key":"BFsrep13462_CR23","doi-asserted-by":"publisher","first-page":"G893","DOI":"10.1152\/ajpgi.00337.2013","volume":"15","author":"B Kong","year":"2014","unstructured":"Kong, B. et al. Fibroblast growth factor 15 deficiency impairs liver regeneration in mice. Am J Physiol Gastrointest Liver Physiol. 15, G893\u2013G902 (2014)","journal-title":"Am J Physiol Gastrointest Liver Physiol."},{"key":"BFsrep13462_CR24","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1136\/gutjnl-2012-302945","volume":"62","author":"I Uriarte","year":"2013","unstructured":"Uriarte, I. et al. Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice. Gut. 62, 899\u2013910 (2013)","journal-title":"Gut."},{"key":"BFsrep13462_CR25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/1471-2407-12-56","volume":"12","author":"S Miura","year":"2012","unstructured":"Miura, S. et al. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma. BMC Cancer. 12: 56. (2012)","journal-title":"BMC Cancer."},{"key":"BFsrep13462_CR26","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1016\/S0002-9440(10)61177-7","volume":"160","author":"K Nicholes","year":"2002","unstructured":"Nicholes, K. et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol. 160, 2295\u20132307 (2002)","journal-title":"Am J Pathol."},{"key":"BFsrep13462_CR27","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1158\/0008-5472.CAN-14-0208","volume":"15","author":"M Zhou","year":"2014","unstructured":"Zhou, M. et al. Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19. Cancer Res. 15, 3306\u20133316 (2014)","journal-title":"Cancer Res."},{"key":"BFsrep13462_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nrgastro.2013.151","volume":"11","author":"FG Schaap","year":"2014","unstructured":"Schaap, F. G., Trauner, M. & Jansen, P. L. Bile acid receptors as targets for drug development. Nat. Rev. Gastroenterol Hepatol. 11, 55\u201367 (2014).","journal-title":"Nat. Rev. Gastroenterol Hepatol"},{"key":"BFsrep13462_CR29","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","volume":"148","author":"GM Hirschfield","year":"2015","unstructured":"Hirschfield, G. M. et al. Efficacy of obeticholic Acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic Acid. Gastroenterology 148, 751\u2013761 (2015).","journal-title":"Gastroenterology"},{"key":"BFsrep13462_CR30","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","volume":"385","author":"BA Neuschwander-Tetri","year":"2015","unstructured":"Neuschwander-Tetri, B. A. et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385, 956\u2013965 (2015).","journal-title":"Lancet"},{"key":"BFsrep13462_CR31","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/hep.27074","volume":"60","author":"E Wunsch","year":"2014","unstructured":"Wunsch, E. et al. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis. Hepatology. 60, 931\u2013940 (2014)","journal-title":"Hepatology"},{"key":"BFsrep13462_CR32","doi-asserted-by":"crossref","unstructured":"EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 51, 237\u2013267 (2009)","DOI":"10.1016\/j.jhep.2009.04.009"},{"key":"BFsrep13462_CR33","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/liv.12030","volume":"33","author":"J Kopycinska","year":"2013","unstructured":"Kopycinska, J. et al. Activation of FoxO3a\/Bim axis in patients with Primary Biliary Cirrhosis. Liver Int. 33, 231\u2013238 (2013)","journal-title":"Liver Int."},{"key":"BFsrep13462_CR34","doi-asserted-by":"crossref","unstructured":"Milkiewicz, M. et al. Ursodeoxycholic acid influences the expression of p27kip1 but not FoxO1 in patients with non-cirrhotic primary biliary cirrhosis. J Immunol Res. 921285. doi: 10.1155\/2014\/921285 (2014)","DOI":"10.1155\/2014\/921285"},{"key":"BFsrep13462_CR35","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/clpt.2013.122","volume":"94","author":"J Trottier","year":"2013","unstructured":"Trottier, J. et al. Profiling serum bile acid glucuronides in humans: gender divergences, genetic determinants and response to fenofibrate. Clin Pharmacol Ther. 94, 533\u2013543 (2013)","journal-title":"Clin Pharmacol Ther."},{"key":"BFsrep13462_CR36","doi-asserted-by":"publisher","first-page":"e22094","DOI":"10.1371\/journal.pone.0022094","volume":"6","author":"J Trottier","year":"2011","unstructured":"Trottier, J. et al. Profiling circulating and urinary bile acids in patients with biliary obstruction before and after biliary stenting. PLoS One 6, e22094 (2011)","journal-title":"PLoS One"},{"key":"BFsrep13462_CR37","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/clpt.2011.124","volume":"90","author":"J Trottier","year":"2011","unstructured":"Trottier, J., Caron, P., Straka, R. J. & Barbier, O. Profile of serum bile acids in noncholestatic volunteers: gender-related differences in response to fenofibrate. Clin Pharmacol Ther 90, 279\u2013286 (2011)","journal-title":"Pharmacol Ther"},{"key":"BFsrep13462_CR38","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.dld.2011.10.025","volume":"44","author":"J Trottier","year":"2012","unstructured":"Trottier, J. et al. Metabolomic profiling of 17 bile acids in serum from patients with primary biliary cirrhosis and primary sclerosing cholangitis: a pilot study. Dig Liver Dis 44, 303\u2013310 (2012)","journal-title":"Dig Liver Dis"},{"key":"BFsrep13462_CR39","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1136\/gut.2005.065862","volume":"54","author":"A Jacoby","year":"2005","unstructured":"Jacoby, A. et al. Development, validation and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis. Gut. 54, 1622\u20131629 (2005)","journal-title":"Gut."},{"key":"BFsrep13462_CR40","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.dld.2010.01.004","volume":"42","author":"L Montali","year":"2010","unstructured":"Montali, L. et al. A short version of a HRQoL questionnaire for Italian and Japanese patients with Primary Biliary Cirrhosis. Dig Liver Dis. 42, 718\u2013723 (2010)","journal-title":"Dig Liver Dis."},{"key":"BFsrep13462_CR41","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr.","year":"1992","unstructured":"Ware, J. E., Jr. & Sherbourne, C. D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 30, 473\u2013483 (1992)","journal-title":"Med Care."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep13462","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep13462.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep13462.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T17:44:42Z","timestamp":1672940682000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep13462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,21]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,10,16]]}},"alternative-id":["BFsrep13462"],"URL":"https:\/\/doi.org\/10.1038\/srep13462","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725731945.793516308","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,21]]},"assertion":[{"value":"27 March 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13462"}}